

Kento Imajo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3320563/kento-imajo-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114
papers

3,014
citations

28
h-index

52
g-index

134
ext. papers

4,117
ext. citations

5
avg, IF

4.85
L-index

#	Paper	IF	Citations
114	Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. <i>Gastroenterology</i> , 2016 , 150, 626-637.e7	13.3	438
113	Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. <i>Cell Metabolism</i> , 2012 , 16, 44-54	24.6	232
112	Involvement of a periodontal pathogen, <i>Porphyromonas gingivalis</i> on the pathogenesis of non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2012 , 12, 16	3	160
111	Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 630-637.e8	6.9	135
110	Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. <i>Cancer</i> , 2016 , 122, 2041-9	6.4	109
109	The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. <i>PLoS ONE</i> , 2016 , 11, e0146337	3.7	105
108	Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. <i>Journal of Gastroenterology</i> , 2014 , 49, 1477-84	6.9	87
107	Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2011 , 46, 1300-6	6.9	77
106	Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 21833-57	6.3	63
105	Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. <i>Scientific Reports</i> , 2017 , 7, 42477	4.9	58
104	Outcomes and factors influencing survival in cirrhotic cases with spontaneous rupture of hepatocellular carcinoma: a multicenter study. <i>BMC Gastroenterology</i> , 2009 , 9, 29	3	56
103	Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2015 , 63, 494-502	13.4	53
102	Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis. <i>Scientific Reports</i> , 2016 , 6, 22251	4.9	48
101	Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin. <i>Scientific Reports</i> , 2018 , 8, 11365	4.9	46
100	Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. <i>Journal of Gastroenterology</i> , 2018 , 53, 181-196	6.9	46
99	Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. <i>BMC Gastroenterology</i> , 2017 , 17, 96	3	40
98	Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2570-2580.e37	6.9	40

97	Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1009-14	4	40
96	Unfolded protein response pathways regulate Hepatitis C virus replication via modulation of autophagy. <i>Biochemical and Biophysical Research Communications</i> , 2013 , 432, 326-32	3-4	39
95	Characteristics of non-obese non-alcoholic fatty liver disease: Effect of genetic and environmental factors. <i>Hepatology Research</i> , 2016 , 46, 1011-8	5-1	39
94	HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1390-1395	4	38
93	The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. <i>Journal of Gastroenterology</i> , 2018 , 53, 1216-1224	6-9	37
92	Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitis. <i>PLoS ONE</i> , 2013 , 8, e65211	3-7	34
91	Liver abscess caused by periodontal bacterial infection with <i>Fusobacterium necrophorum</i> . <i>Hepatology Research</i> , 2011 , 41, 194-6	5-1	34
90	Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. <i>Journal of Gastroenterology</i> , 2016 , 51, 586-96	6-9	33
89	Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. <i>Journal of Gastroenterology</i> , 2013 , 48, 1051-60	6-9	29
88	Microbiota and nonalcoholic steatohepatitis. <i>Seminars in Immunopathology</i> , 2014 , 36, 115-32	12	29
87	Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. <i>Journal of Gastroenterology</i> , 2020 , 55, 428-440	6-9	29
86	<i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 1795-1803	4	27
85	Prevalence of pruritus in patients with chronic liver disease: A multicenter study. <i>Hepatology Research</i> , 2018 , 48, E252-E262	5-1	27
84	A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. <i>Scientific Reports</i> , 2018 , 8, 10434	4-9	25
83	LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study. <i>PLoS ONE</i> , 2014 , 9, e115403	3-7	25
82	Identification of the genomic region under epigenetic regulation during non-alcoholic fatty liver disease progression. <i>Hepatology Research</i> , 2018 , 48, E320-E334	5-1	23
81	Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution. <i>BMC Gastroenterology</i> , 2015 , 15, 177	3	23
80	Plasma free choline is a novel non-invasive biomarker for early-stage non-alcoholic steatohepatitis: A multi-center validation study. <i>Hepatology Research</i> , 2012 , 42, 757-66	5-1	23

79	Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	22
78	Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2020 , 50, 682-692	5.1	22
77	Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes. <i>Hepatology Research</i> , 2020 , 50, 831-839	5.1	21
76	Transient elastography for monitoring the fibrosis of non-alcoholic fatty liver disease for 4 years. <i>Hepatology Research</i> , 2013 , 43, 979-83	5.1	21
75	Identification of differentially methylated region (DMR) networks associated with progression of nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2018 , 8, 13567	4.9	21
74	Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model. <i>BMC Gastroenterology</i> , 2015 , 15, 42	3	20
73	Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	20
72	Evaluation of the Liver Fibrosis Index calculated by using real-time tissue elastography for the non-invasive assessment of liver fibrosis in chronic liver diseases. <i>Hepatology Research</i> , 2013 , 43, 735-42	5.1	18
71	MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Gut</i> , 2021 , 70, 1946-1953	19.2	18
70	Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: Proceed with caution. <i>Hepatology Research</i> , 2014 , 44, E499-502	5.1	17
69	Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 10108-14	5.6	16
68	Magnetic resonance elastography increases usefulness and safety of non-invasive screening for esophageal varices. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 2022-2028	4	15
67	Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 69-82	4	15
66	Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. <i>BMJ Open Diabetes Research and Care</i> , 2021 , 9,	4.5	14
65	Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARM α) versus placebo in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 1263-1277	6.1	14
64	Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1626-1632	4	12
63	Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study. <i>JGH Open</i> , 2020 , 4, 497-502	1.8	12
62	Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study. <i>BMC Gastroenterology</i> , 2020 , 20, 88	3	12

61	Emerging drugs for non-alcoholic steatohepatitis. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 279-90	3.7	12
60	Time-course of changes of visceral fat area, liver volume and liver fat area during intragastric balloon therapy in Japanese super-obese patients. <i>Internal Medicine</i> , 2011 , 50, 2449-55	1.1	12
59	Three-dimensional analysis of pancreatic fat by fat-water magnetic resonance imaging provides detailed characterization of pancreatic steatosis with improved reproducibility. <i>PLoS ONE</i> , 2019 , 14, e02214921	3.7	12
58	Non-Invasive Diagnosis of Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1409-1411	0.7	12
57	Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019 , 49, 1136-1146	5.1	11
56	A review of conventional and newer generation microwave ablation systems for hepatocellular carcinoma. <i>Journal of Medical Ultrasonics (2001)</i> , 2020 , 47, 265-277	1.4	11
55	Angiotensin II Type 1 Receptor-associated Protein Inhibits Angiotensin II-induced Insulin Resistance with Suppression of Oxidative Stress in Skeletal Muscle Tissue. <i>Scientific Reports</i> , 2018 , 8, 2846	4.9	11
54	Peroxisome Proliferator-Activated Receptor Gamma Exacerbates Concanavalin A-Induced Liver Injury via Suppressing the Translocation of NF- κ B into the Nucleus. <i>PPAR Research</i> , 2012 , 2012, 940384	4.3	11
53	Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?. <i>World Journal of Gastroenterology</i> , 2012 , 18, 1933-9	5.6	11
52	Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	11
51	Identification of core gene networks and hub genes associated with progression of non-alcoholic fatty liver disease by RNA sequencing. <i>Hepatology Research</i> , 2017 , 47, 1445-1458	5.1	10
50	Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019 , 49, 872-880	5.1	10
49	Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver. <i>Diagnostics</i> , 2020 , 10,	3.8	9
48	New microwave ablation system for unresectable liver tumors that forms large, spherical ablation zones. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 2007-2014	4	9
47	Hepatic triglyceride lipase plays an essential role in changing the lipid metabolism in genotype 1b hepatitis C virus replicon cells and hepatitis C patients. <i>Hepatology Research</i> , 2013 , 43, 1190-8	5.1	9
46	Endotoxins and Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2021 , 12, 770986	5.7	9
45	Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. <i>Hepatology Communications</i> , 2021 ,	6	9
44	Advances in ultrasound elastography for nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2020 , 47, 521-533	1.4	8

43	Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2020 , 10,	3.8	8
42	Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. <i>World Journal of Gastroenterology</i> , 2021 , 27, 609-623	5.6	8
41	Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). <i>Contemporary Clinical Trials Communications</i> , 2020 , 17, 100516	1.8	7
40	Uric acid levels decrease with fibrosis progression in patients with nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2014 , 47, 1138-9	3.5	7
39	Novel findings for the development of drug therapy for various liver diseases: Liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis. <i>Journal of Pharmacological Sciences</i> , 2011 , 115, 270-3	3.7	7
38	Induction of microsomal triglyceride transfer protein expression is a candidate mechanism by which ezetimibe therapy might exert beneficial effects in patients with nonalcoholic steatohepatitis. <i>Journal of Gastroenterology</i> , 2011 , 46, 415-6; author reply 417	6.9	7
37	Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin. <i>Hepato-Gastroenterology</i> , 2012 , 59, 1522-5		7
36	Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 996-1007	18.8	7
35	Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. <i>Hepatology Communications</i> , 2021 , 5, 559-572	6	7
34	Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: A multicenter study. <i>Hepatology Research</i> , 2020 , 50, 955-965	5.1	6
33	Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis. <i>Journal of Gastroenterology</i> , 2014 , 49, 295-304	6.9	6
32	Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. <i>Journal of Gastroenterology</i> , 2021 , 56, 1022-1032	6.9	6
31	Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2020 , 47, 535-548	1.4	6
30	Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 2275-2284	4.1	6
29	FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. <i>Life</i> , 2021 , 11,	3	6
28	MRE plus FIB-4 (MEFIB) versus FAST in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Hepatology</i> , 2021 ,	11.2	6
27	Characteristics of Fecal Microbiota in Japanese Patients with Nonalcoholic Fatty Liver Disease: A Connection among Gut-Permeability, Endotoxin and NAFLD. <i>Gastroenterology</i> , 2017 , 152, S1200	13.3	5
26	The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2014 , 49, 1163-74	6.9	4

25	Vitamin B6 efficacy in the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, single-center trial. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2021 , 68, 181-186	3.1	4
24	The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
23	Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1411-1416	4	4
22	Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. <i>Contemporary Clinical Trials</i> , 2018 , 69, 40-47	2.3	3
21	Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.. <i>Hepatology</i> , 2021 ,	11.2	3
20	Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs. <i>Diagnostics</i> , 2020 , 10,	3.8	3
19	Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease. <i>BMJ Open</i> , 2020 , 10, e037961	3	3
18	Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study. <i>Trials</i> , 2020 , 21, 453	2.8	2
17	FRI-312-Increased levels of bile acid in feces plays an important role in pathophysiology of non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2019 , 70, e534	13.4	2
16	Utility of Ultrasound-Guided Attenuation Parameter for Grading Steatosis With Reference to MRI-PDFF in a Large Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
15	Are platelets count useful for detecting the grade of steatosis?. <i>Hepatitis Monthly</i> , 2015 , 15, e28957	1.8	2
14	Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. <i>Metabolism: Clinical and Experimental</i> , 2022 , 126, 154911	12.7	2
13	Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort. <i>PLoS ONE</i> , 2021 , 16, e0249491	3.7	2
12	Diagnostic Accuracy of Two-Dimensional Shear Wave Elastography for Liver Fibrosis: A Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
11	Acoustic radiation force-based shear stiffness and non-invasive panels of tests in Japanese patients with nonalcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2012 , 56, 740-1	13.4	1
10	Two-step strategy, FIB-4 followed by magnetic resonance elastography, for detecting advanced fibrosis in NAFLD.. <i>Clinical Gastroenterology and Hepatology</i> , 2022 ,	6.9	1
9	MRI-Based Quantitative R2 Mapping at 3 Tesla Reflects Hepatic Iron Overload and Pathogenesis in Nonalcoholic Fatty Liver Disease Patients. <i>Journal of Magnetic Resonance Imaging</i> , 2021 ,	5.6	1
8	Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease. <i>Internal Medicine</i> , 2021 , 60, 3391-3399	1.1	1

7	Gastroesophageal varices evaluation using spleen-dedicated stiffness measurement by vibration-controlled transient elastography.. <i>JGH Open</i> , 2022 , 6, 11-19	1.8	1
6	Infection phase is a predictor of pruritus in patients with hepatitis B virus infection. <i>Biomedical Reports</i> , 2019 , 11, 63-69	1.8	0
5	Screening of nonalcoholic fatty liver disease in patients with coronary heart disease by transient elastography: proceed with caution. <i>Wiener Klinische Wochenschrift</i> , 2015 , 127, 75-6	2.3	
4	Reply. <i>Gastroenterology</i> , 2016 , 151, 375-6	13.3	
3	Microbiota in Non-alcoholic Liver Disease 2019 , 103-111		
2	VI. Screening High-risk Non-alcoholic Fatty Liver Disease (NAFLD). <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020 , 109, 47-55	0	
1	A case of hepatitis B virus reactivation with hemochromatosis after allogeneic bone marrow transplantation for acute myeloid leukemia. <i>Acta Hepatologica Japonica</i> , 2020 , 61, 504-512	0.3	